A5015811269- Venous Thromboembolism Diagnosis and Management
- Blood groups and transfusion
- Hemoglobinopathies and Related Disorders
- Platelet Disorders and Treatments
- Acute Myeloid Leukemia Research
- Acute Myocardial Infarction Research
- Atrial Fibrillation Management and Outcomes
- Autoimmune Bullous Skin Diseases
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Blood Coagulation and Thrombosis Mechanisms
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematological disorders and diagnostics
- Hemophilia Treatment and Research
- Reproductive Biology and Fertility
- Ultrasound in Clinical Applications
- Heparin-Induced Thrombocytopenia and Thrombosis
- Case Reports on Hematomas
- Oral and gingival health research
- Cardiac Arrhythmias and Treatments
- Clinical practice guidelines implementation
- Erythrocyte Function and Pathophysiology
- Erythropoietin and Anemia Treatment
- Cancer Risks and Factors
- Blood disorders and treatments
Monash Health
2016-2025
Monash University
2016-2024
Monash Medical Centre
2015-2022
Austin Health
2020
Austin Hospital
2016
University of Amsterdam
2000
Introduction Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cardiovascular disease and, globally, more than an estimated 10 million people have it yearly. It a chronic recurrent disease. The symptoms of VTE are non-specific diagnosis should actively be sought once considered. mainstay treatment anticoagulation, with few patients requiring additional intervention. A working group experts in area recently completed...
After pharmaceutical benefits scheme approval of midostaurin for fms-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia (AML) in 2018, the Australasian Leukaemia & Lymphoma Group (ALLG) proposed a consensus approach to AML induction with 7+3 chemotherapy (7 days infusional cytarabine three doses anthracycline) align future clinical trial protocols. To determine efficacy and safety idarubicin-based ± (per ALLG recommendations) real-world, tertiary hospital setting. Data were...
Introduction The absence of high quality evidence for basic clinical dilemmas in immune thrombocytopenic purpura (ITP) underlines the need contemporary guidelines relevant to local treatment context. ITP is diagnosed by exclusions, with a hallmark laboratory finding isolated thrombocytopenia. Main recommendations Bleeding, family and medication histories review historical investigations are required gauge bleeding risk possible hereditary syndromes. Beyond platelet count, decision treat...
There is currently minimal data on fertility outcomes in premenopausal women undergoing autologous stem cell transplant (ASCT) with carmustine, etoposide, cytarabine and melphalan (BEAM) conditioning. A retrospective analysis of females aged between 18 40 yr who underwent BEAM/ASCT for lymphoma 1995 2011 was performed at four centres. Of 41 BEAM conditioning, 25 met the inclusion criteria main exclusion criterion being inadequate documentation. Eighteen had Hodgkin lymphoma, seven...
The ADJUST-PE study showed that an age-adjusted D-dimer (AADD) (age years × 10 ng/mL if >50 years) combined with unlikely pre-test probability (PTP) can increase the proportion of older patients in whom pulmonary embolism (PE) be safely excluded, but IL HS assay was not assessed. To assess ability to exclude PE using AADD.Retrospective analysis consecutive presenting symptoms acute one three Monash Health Emergency Departments (January 2013-January 2014) who had computed tomography...
Abstract Anti-Di a can mediate hemolytic disease of the fetus and newborn, but it is unclear if cause transfusion reactions (HTRs). To date, there has only been one report possible immediate HTR attributed to anti-Di . Our case details an due in patient with pre-existing liver failure. This reaction triggered multi-organ failure, subsequently died. also highlights importance considering HTRs even when routine antibody screening unremarkable, particularly electronic crossmatch used, because...
Ferric carboxymaltose is increasingly utilised to treat iron deficiency and usually diluted in saline administered as an intravenous infusion over 15 min. Although this highly convenient compared with older formulations, we hypothesised the drug could be administered, safely given a rapid bolus injection.To define risk of serious adverse events following administration undiluted, rapid, high-dose ferric injection. Secondary aims included all other events, well longitudinal effects on...